drugset / Trial / NCT00246610
Safety Of VIRACEPT® 625mg Administered To HIV-Infected Women During Pregnancy
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study is an evaluation of the safety of 625 mg formulation when administered to HIV-infected pregnant women from their second trimester through six weeks postpartum. The study will also evaluate the pharmacokinetics of VIRACEPT
Timeline
- Start
- 2006-03
- Primary completion
- 2007-11
- Completion
- 2007-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nelfinavir | Other / unclassified | 1250 mg | Oral |
| Background | Lamivudine | Other / unclassified | 150 mg | Oral |
| Background | Zidovudine | Small molecule | 300 mg | Oral |